Please login to the form below
Dr Reddy's
This page shows the latest Dr Reddy's news and features for those working in and with pharma, biotech and healthcare.
Amarin shares tumble following Vascepa patent loss
Dr Reddy’s Laboratories and Hikma Pharmaceuticals are already queueing up to launch generic versions of Vascepa, with Hikma reporting that it is working with the FDA to gain approval for ... The patent ruling only applies to Vascepa’s US patent
Latest news
-
GSK and Apotex join generic Zantac recalls as carcinogen concerns mount
Reddy’s Laboratories and Saraca Laboratories. A spokeswoman for GSK, Kristen Neese, reportedly said in an email that Dr. ... Reddy’s has an FDA-approval to sell its own versions of prescription and OTC generic Zantac in the US.
-
Triplet approvals for myeloma boost Celgene in Q2
Revlimid gained on the back of its recent approval alongside Takeda’s Velcade (bortezomib) and dexamethasone as a first-line therapy for adults with multiple myeloma who are not eligible for ... Dr Reddy’s that reduce the risk of a generic entering
-
Indivior push to diversify boosted by schizophrenia drug approval
The two approvals come as Indivior is fighting a rearguard action to protect Suboxone from a generic developed by Dr Reddy’s Laboratories. ... Reddy’s generic earlier this month.
-
Indivior slumps as patent dispute rises US generic spectre
Indivior said it plans to appeal the decision, which held that three US patents on Suboxone were valid but that a generic from Indian drugmaker Dr Reddy's Laboratories drug does ... He said that Dr Reddy's has not yet been granted FDA approval for its
-
Fresenius Kabi buys Akorn and Merck's biosimilar businesses
Adding in Merck's biosimilars business takes it right back into the biotech sphere. ... Merck kicked off its biosimilar programme in 2012 via an agreement with India's Dr Reddy's Laboratories at a time when the company was facing patent expiries on some
More from news
Approximately 3 fully matching, plus 54 partially matching documents found.
Latest Intelligence
-
Deal Watch September 2016
Dr Reddy's has expanded its collaboration with Amgen in India adding three approved products: Xgeva for treating bone metastases, Vectibix in colorectal cancer therapy and Prolia for osteoporosis. ... Upfront $80m plus $830m in milestones [ex S. Korea].
-
Deal Watch June 2016
The three deals with Mayne Pharma, Impax Laboratories and Dr Reddy's, for a combined value of over $1.5bn, cover portfolios of marketed and approved generic drugs, drugs currently pending ... acquisition assets/ return of rights. 586. Teva and Allergan/
-
Deal Watch March 2016
Two deals involved products at a later stage of development: Dr Reddy's licence for Xenoport's phase II product XP23829 for plaque psoriasis, and Ipsen's licence for Exelixis's ... Collaboration – development. $595. Xenoport/ Dr Reddy's. XP-23829 for
-
Medius Deal Watch table for April 2015
The top major pharma mergers, acquisitions and collaborations during the month continued pharma's love affair with oncology. ... 151. UCB/ Dr. Reddy's. Business acquisition. Dermatology, respiratory and paediatric products for South Asia.
-
Pharma deals in April 2015
Dr Reddy's, Menarini and Cipher Pharmaceuticals have acquired or licensed rights to products in South Asia, Asia Pacific (ex-Japan) and North America and Mexico, respectively. ... Previously rumoured, Dr Reddy's acquires rights to dermatology,
More from intelligence
Approximately 0 fully matching, plus 9 partially matching documents found.
Latest appointments
-
Dr Reddy's makes senior changes as US generics head exits
UmangVohra will be replaced by Alok Sonig. Dr Reddy's has appointed Alok Sonig to be its new head of North America generics to take over from Umang Vohra (pictured). ... Vohra's replacement at Dr Reddy's is the company's head of India generics Alok Sonig
-
MedImmune appoints Dr Anand Subramony
While at Novartis Dr Subramony established and headed company's novel delivery technologies and therapeutics group. ... Prior to that he held leadership positions at Dr. Reddy's Laboratories in Bridgewater, New Jersey and Johnson &Johnson/Alza
-
Pegasus recruits corporate services lead
His team's first priority, Mackenzie-Reid added, was to ensure the market understands Pegasus'new proposition. ... Clients include Bayer, Novo Nordisk, Fittleworth, Dr Reddy's and Holland &Barrett.
-
New global head of HR for Dr Reddy’s
Sripada Chandrasekhar joins from IBM. Hyderabad, India-headquartered Dr Reddy's Laboratories has appointed a former IBM executive president and global head of human resources. ... Chakraborty remains with Dr Reddy's, and has retained all but the HR
-
Dr Reddy’s appoints Umang Vohra to lead US business
Will be replaced as chief financial officer by Saumen Chakraborty. Indian generics company Dr Reddy's Laboratories has appointed Umang Vohra as the new head of its North American business. ... He first joined the company in 2002, moving from Pepsico-India
More from appointments
Approximately 2 fully matching, plus 3 partially matching documents found.
Subscribe to our email news alerts
- Strategy Director - Healthcare Advertising
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
- Associate Director - Global Healthcare Consulting
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- MHRA to introduce new UK clinical trials framework
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- 2023 PM Society Awards – winners announced
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- Pfizer and Astellas’ Xtandi shows promise in phase 3 prostate cancer study
- AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
- WHO report highlights impact of COVID-19 pandemic on non-communicable diseases
- Critical success factors and the increasing value of rare disease clinical trials
- Quantum Computing, Artificial Intelligence, & Machine Learning for Drug Discovery
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- Biogen and Eisai’s Alzheimer’s drug to be covered by US Veterans Health Administration
- VR/AR Applications for Training and Healthcare
Latest intelligence
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
- Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
- Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...
